Trimetazidine effects on postinfarction remodeling of the left ventricle
Kokov, A.N.; Tarasov, I.I.; Barbarash, L.S.
Terapevticheskii Arkhiv 77(8): 10-14
2005
ISSN/ISBN: 0040-3660 PMID: 16206598 Document Number: 588750
Aim. To study effects of combined therapy including trimetazidine on morphofunctional indices of the left ventricle (L P).Material and methods. Seventy five patients with primary macrofocal myocardial infarction (MI) were randomized into two groups: 38 patients of group I received combination of bisoprolol, a beta-adrenoblocker, and analapril, an ACE inhibitor, in individually adjusted dose under control of blood pressure (BP) and blood creatinine; 37 patients of group 2 received the same combination and trimetazidine in a dose 70 mg/day for 6 months beginning on postinfarction day 7-10. Each group contained a subgroup treated with systemic thrombolytic streptokinase at admission. MR imaging (MRI) and cine-MRI assessed morphofunctional LV parameters.Results. A 6-month therapy with trimetazine resulted in a significant regress of the morphofunctional alterations associated with L V remodeling in postmyocardial infarction patients.Conclusion. Combined treatment including systemic thrombolysis with streptokinase within MI hours 0-6, trimetasidine on MI day 7-10 plus 6 months significantly inhibits pathological postinfarction L V remodeling.